Elucidation of this metabolic regulatory network provides theoretical foundation for combination therapies targeting PI3K–AKT–mTOR pathway inhibitors, with preclinical studies confirming their ability to significantly sensitize tumor cells to FINs. This evidence concerns the gene MTOR and neoplasm.